2025年1月7日 · Fenoflex is a fibrate that activates peroxisome proliferator activated receptor alpha (PPARα) to alter lipid metabolism and treat primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia. Fenoflex requires once daily dosing and has a half life of 19-27 hours so its duration of action is long.

2023年11月13日 · Fenofibrate is a medicine used with a cholesterol-reducing diet to lower high cholesterol and high triglyceride (fatty acid) levels in the blood. It works by increasing the breaking down and removal of triglycerides from the blood.

Fenoflex Capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides (TG) and apolopoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

2024年7月1日 · Fenofibrate is commonly used to lower bad cholesterol (LDL-C) and increase good cholesterol (HDL-C) in people with high cholesterol or mixed dyslipidemia (elevated cholesterol and triglycerides)....

FENOFLEX 160MG CAPSULE. Indications / Uses : Adjunctive therapy to diet for the reduction of LDL-cholesterol, total cholesterol, triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb hyperlipidemia).

Fenoflex tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

Fenoflex is used as adjunctive therapy for the reduction of LDL-cholesterol, total cholesterol, triglycerides, and apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

2025年2月20日 · Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb).

2023年6月26日 · Fenoflex is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides (TG) and apolopoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

Adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Treatment of secondary hyperlipoproteinemia is indicated if the hyperlipoproteinemia persists despite effective treatment of the underlying disease (e.g., dyslipidemia in diabetes mellitus).